Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus ARMODAFINIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus ARMODAFINIL.
ADZENYS ER vs ARMODAFINIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Armodafinil is a wakefulness-promoting agent. Its mechanism is unclear but may involve inhibition of dopamine reuptake, leading to increased extracellular dopamine levels. It also affects orexin, histamine, norepinephrine, and GABA pathways.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
Adults: 150-250 mg orally once daily in the morning for narcolepsy or obstructive sleep apnea; 200-400 mg orally once daily for shift work disorder.
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil."
Clinical Note
moderateCyclophosphamide + Armodafinil
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
12–15 hours (terminal) in adults; longer in hepatic impairment (e.g., 20–30% increase with cirrhosis).
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal: ~80% as metabolites (major: armodafinil acid, minor: modafinil sulfone); fecal: <1% unchanged; biliary: negligible.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Armodafinil can be decreased when combined with Cyclophosphamide."